Lantern Pharma | Third Quarter 2022 Operating & Financial Results Conference Call

Lantern’s Q3 2022 earnings call webinar provides updates including the activation of the first trial sites for the Phase 2 Harmonic™ trial, newly issued patent for drug candidate LP-300, development updates for drug candidates LP-184 & LP-284, datapoint and algorithm growth for AI-platform RADR®, and financial updates.
Read the full press release here bit.ly/43h7Dpk